TNFRSF17 and Miyoshi myopathy: FDA-approved B-cell maturation antigen (BCMA)-targeting CAR T cell immunotherapies [11], monoclonal antibodies that target CD38 [12, 13] or BCMA [14, 15], and bispecific T cell engager (BiTE) antibody [16–18] have achieved great success in relapsed and refractory MM.